This House resolution says that more than 25 years of real-world evidence and hundreds of peer-reviewed studies show mifepristone is safe and effective. It calls for laws and agency rules that affect access to medication abortion to be equitable, transparent, and based on the best available peer-reviewed science. The text notes that the Food and Drug Administration (FDA) approved mifepristone after extensive review, that the FDA has repeatedly reviewed its safety, and that in 2023 the FDA modified the REMS for mifepristone to allow certified pharmacies to dispense it in person or by mail and to allow prescription by certified prescribers. The resolution cites endorsements of mifepristone safety from many medical organizations and international bodies, and it says medication abortion made up 63 percent of U.S. abortions in 2023. It also describes how abortion bans and restrictions since Dobbs v. Jackson Women's Health Organization have reduced access in some states and says restrictions disproportionately harm certain groups.
This resolution expresses the House's view; it does not itself change FDA rules or create new law. It urges that FDA decisions and related policies be based on scientific evidence and consider burdens on patient access. The resolution supports preserving the ability to prescribe mifepristone by telemedicine and to dispense it by certified pharmacies or mail. It highlights that changes to access may affect people who already face health inequities.
No publicly available information.
Supporters in the resolution say the FDA has repeatedly found mifepristone safe and effective after clinical trials and many years of real-world use. They note the FDA's 2023 REMS modification that allowed certified pharmacies and mail dispensing, and they cite endorsements from major medical groups and the World Health Organization. The resolution argues that keeping or expanding access to medication abortion, including telemedicine and pharmacy dispensing, is important to maintain equitable care and to reduce barriers faced by people in rural areas, people with low incomes, people of color, immigrants, LGBTQ+ people, people with disabilities, and people experiencing intimate partner violence.
No publicly available information.